Open your EHR right now and run a quick filter. Pull up every patient who hasn't had an appointment, a lab order, or any form of contact in the last 90 days.
That list is probably longer than you expected.
Now multiply it by $15,000. That's the industry average annual value of a longevity medicine patient, according to practice management data across the functional medicine and hormone optimization space.
If you have 80 inactive patients on that list, you're looking at an estimated $1.2 million in annual revenue sitting dormant in your system. Not lost to a competitor. Not gone forever. Just... sitting there. Waiting for someone to reach out.
Most clinics never do.
Instead, they pour money into acquiring new patients. They run Facebook ads, sponsor local events, offer free consultations, and invest in SEO campaigns. Industry estimates suggest that acquiring a single new longevity patient costs between $500 and $2,000 when you factor in marketing spend, staff time, and the free or discounted initial consultation that many practices offer.
Meanwhile, the patients who already walked through your door, already trusted you with their health, already started an NAD+ protocol or a hormone optimization program or a peptide therapy cycle, are sitting in a database that nobody is looking at.
This is the re-engagement gap. And for most longevity clinics, it represents the single highest-ROI opportunity they're not pursuing.
They Didn't Leave. They Drifted.
Here is the most important thing to understand about lapsed patients in longevity medicine: the vast majority did not make a conscious decision to quit.
They didn't call your office and say “I'm done.” They didn't switch to a competitor. They didn't decide the protocols were ineffective. In most cases, what happened was far more mundane. Life got in the way.
A work trip disrupted their supplement routine and they never got back on track. A busy month meant they postponed their LabCorp requisition “until next week,” and next week became next month. The initial energy boost from their first NAD+ infusion plateaued, and without anyone from your clinic reaching out to explain that plateaus are normal, doubt crept in. Their BPC-157 supply ran out and reordering felt like one more thing on an already full to-do list.
Published adherence research consistently points to the same pattern. Patients who disengage from long-term treatment protocols rarely do so because of dissatisfaction. They disengage because of friction, ambiguity, and silence.
This distinction matters enormously for re-engagement. A patient who actively decided to leave requires persuasion. A patient who drifted away requires a nudge. And nudges are cheap, simple, and remarkably effective when done right.
Why Your NAD+ Patients Quit After 90 Days
The Math That Should Change Your Marketing Budget
Let's walk through the economics of re-engagement versus acquisition.
Based on industry estimates, acquiring a new longevity patient costs $500 to $2,000. Re-engaging a lapsed one costs a fraction of that.
A new patient requires awareness, trust-building, education, and conversion. Every one of those steps costs money and time.
A lapsed patient has already cleared every one of those hurdles. They know your name. They've met your staff. They understand what NAD+ therapy or testosterone replacement or peptide therapy involves because they've already experienced it.
Based on our retention modeling, consider a mid-sized longevity clinic with 200 total patients, 80 of whom have gone inactive in the past 6 to 12 months. Industry re-engagement benchmarks suggest that a well-executed win-back campaign can reactivate roughly 30% to 40% of lapsed patients.
That's 24 to 32 patients. At an estimated average value of $15,000 per year, that's a projected $360,000 to $480,000 in recovered annual revenue. Compare that to acquiring the same number of new patients from scratch at $1,000 per acquisition — $24,000 to $32,000 in marketing spend alone.
The return on re-engagement isn't marginally better than acquisition. It's an order of magnitude better.
Why Most Win-Back Attempts Fail
Some clinics do try to re-engage lapsed patients. Usually it looks like a front desk coordinator pulling a list, making phone calls, and leaving voicemails that go unreturned. Or a mass email blast saying “We miss you!”
These efforts almost always underperform.
Generic outreach feels like spam. A patient who was on a specific rapamycin cycling protocol does not want to receive the same “we miss you” email as a patient who came for a single consultation. When every lapsed patient gets the same message, none of them feel seen.
Timing is everything, and manual outreach can't get it right. Published healthcare retention data suggests patients contacted within 30 to 45 days of last activity are significantly more responsive than those contacted at 90 or 120 days.
Phone calls are high-effort, low-yield. People don't answer calls from numbers they don't recognize. A front desk coordinator spending 3 hours making calls might connect with 5 or 6 patients.
There's no system to track what works. Without tracking and iteration, every re-engagement attempt is a shot in the dark.
What Effective Re-Engagement Actually Looks Like
A2V2.ai is designed to treat re-engagement as a structured, data-driven, automated system.
The platform is designed to detect inactivity early, typically within 30 to 45 days of a patient's last meaningful touchpoint. Rather than waiting for a staff member to notice, the system is designed to flag the patient automatically and initiate a tailored re-engagement sequence.
Protocol-specific personalization is at the core. A patient who drifted from an NAD+ protocol receives a different message than one who completed a full HRT cycle but didn't schedule follow-up labs. The message isn't “we miss you.” It's “we noticed you haven't completed your 90-day labs for your hormone panel.”
The tone is designed to be warm, not guilty. Effective re-engagement acknowledges the gap without judgment, normalizes the difficulty of maintaining protocols, and focuses on making the return frictionless.
Multi-channel sequencing is designed to meet patients where they are — SMS, email, and patient portal outreach in a coordinated sequence, adjusting based on response patterns.
Everything is designed to run within full HIPAA compliance. Every message encrypted, logged, and compliant. No PHI exposed to external systems.
The system is designed to learn. Which messages get the highest response rates? What's the optimal number of touchpoints? Over time, the platform is designed to optimize based on real engagement data.
Your AI Is a HIPAA Violation Waiting to Happen
The Patients Worth Recovering First
Not every lapsed patient represents the same opportunity.
High-protocol-value patients should be at the top. A patient midway through a six-month NAD+ series represents significantly more projected lifetime value than a single-consultation patient.
Recently lapsed patients respond at higher rates. Published data shows recency is the strongest predictor of re-engagement success.
Patients who showed early engagement signals before dropping off are strong candidates — they demonstrated commitment and likely need the smallest nudge.
Patients on protocols requiring continuity benefit most. Hormone optimization, rapamycin cycling, senolytics, and peptide therapy all produce diminishing results when interrupted.
Your Patients Are Generating Health Data 24/7
A Re-Engagement Audit for Your Practice
Five steps to quantify your re-engagement opportunity:
- 1Pull your inactive patient list (no activity in 60-120 days). Count them. Multiply by $15,000.
- 2Segment by protocol type — NAD+, HRT, peptide therapy, rapamycin, senolytics.
- 3Check your last outreach attempt — when was it? Was it generic?
- 4Audit your compliance — are you reaching out through HIPAA-compliant channels?
- 5Calculate your acquisition cost comparison — if it’s north of $500, re-engagement math wins.
The clinics that build systematic re-engagement workflows today won't just recover revenue — they'll build a compounding advantage. Every patient you bring back is a patient your competitor doesn't get to acquire.
The Silent Revenue Killer in Longevity Medicine · AI for Longevity Clinics
